Search Results - "tyrosine kinase"

Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis by Kinga Krawczyk, Katarzyna Śladowska, Przemysław Holko, Paweł Kawalec

Connect to this object online.

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy by Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han

Connect to this object online.

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors by Ning Luo, Hu Li, Yindeng Luo, Peng Hu, Luwen Liang, Rong Zhang, Dazhi Zhang, Dachuan Cai, Juan Kang

Connect to this object online.

9,10-Dioxoanthracenyldithiocarbamates effectively inhibit the proliferation of non-small cell lung cancer by targeting multiple protein tyrosine kinases by Mateusz Olszewski, Maryna Stasevych, Viktor Zvarych, Natalia Maciejewska

Connect to this object online.

Application of biological medicinal products and tyrosine kinase inhibitors in rheumatoid arthritis and COVID-19: A systematic review of scientific literature by Iva Parvova, Emanuil Yordanov, Emil Hristov, Valentina Petkova

Connect to this object online.

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease by Mirella Pastore, Stefania Grimaudo, Rosaria Maria Pipitone, Giulia Lori, Chiara Raggi, Chiara Raggi, Salvatore Petta, Fabio Marra

Connect to this object online.

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? by Ou SH, Soo RA

Connect to this object online.

Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis by Qilei Chen, Wenmin Zhou, Yueming Huang, Yuanyang Tian, Sum Yi Wong, Wing Ki Lam, Ka Yee Ying, Jianye Zhang, Hubiao Chen

Connect to this object online.

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors by Haiyan Xu, Guangjian Yang, Runze Liu, Yaning Yang, Weihua Li, Junling Li, Xuezhi Hao, Puyuan Xing, Yan Wang

Connect to this object online.

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Chao-Ju Chen, Yu-Peng Liu

Connect to this object online.

Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report by Michelle Hyunju Lee, Amy Song, Julie Y. Li

Connect to this object online.

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors by Liu D, Offin M, Harnicar S, Li BT, Drilon A

Connect to this object online.

QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors by Mourad Aloui, Mohammed Er-rajy, Hamada Imtara, Amina Goudzal, Sara Zarougui, Mohamed El fadili, David E. Arthur, Ramzi A. Mothana, Omar M. Noman, Mahmoud Tarayrah, Elhalaoui Menana

Connect to this object online.

A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context by Nicholas Van Rooij, MD, Jesse Johnston, MBBS, FACD, Rohan Mortimore, MBBS, FRCPA, Ivan Robertson, MBBS, FACD

Connect to this object online.

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia by Yeojae Kim, Yeojae Kim, Seongkoo Kim, Jong Mi Lee, Jong Mi Lee, Ari Ahn, Jae Won Yoo, Jae Wook Lee, Bin Cho, Nack-Gyun Chung, Yonggoo Kim, Yonggoo Kim, Myungshin Kim, Myungshin Kim

Connect to this object online.

Imatinib induces diastolic dysfunction and ventricular early-repolarization delay in the halothane-anesthetized dogs: Class effects of tyrosine kinase inhibitors by Koki Chiba, Ryuichi Kambayashi, Mayu Onozato, Ai Goto, Hiroko Izumi-Nakaseko, Yoshinori Takei, Akio Matsumoto, Koichiro Tanaka, Yasunari Kanda, Takeshi Fukushima, Atsushi Sugiyama

Connect to this object online.

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, Exerts Anti-Inflammatory Activity via Inhibiting STAT1/3 Signaling Pathways by Guo R, Liao H, Meng Y, Shi X, He Y, Zhu Z, Guo W

Connect to this object online.

Analysis of the pharmacotherapeutic effectiveness of the tyrosine kinase inhibitors therapy in patients with Chronic Myeloid Leukemia in a single hematology center in Plovdiv, Bulgaria by Veselina Goranova-Marinova, Daniela Grekova, Vania Georgieva, Kalina Andreevska, Yana Gvozdeva, Margarita Kassarova, Zhanet Grudeva-Popova

Connect to this object online.

Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS by Wen Jiang, Tingting Zhao, Xiaolan Zhen, Chengcheng Jin, Hui Li, Jing Ha

Connect to this object online.

Evaluation of Solubility, Dissolution Rate, and Oral Bioavailability of β-Cyclodextrin and Hydroxypropyl β-Cyclodextrin as Inclusion Complexes of the Tyrosine Kinase Inhibitor, Alectinib by Bashar J. M. Majeed, Mohammed A. Saadallah, Israa H. Al-Ani, Mohamed K. El-Tanani, Khaldun M. Al Azzam, Hassan H. Abdallah, Feras Al-Hajji

Connect to this object online.